Hematologic response in patients with acute lymphoblastic leukemia
| Hematologic response . | ALL . | LyBC . | ||
|---|---|---|---|---|
| All responses, N = 48 . | Sustained responses, N = 48 . | All responses, N = 8 . | Sustained responses, N = 8 . | |
| Overall, no. (%) | 29 (60) | 13 (27) | 4 (50) | 2 (25) |
| 95% CI, % | 45.3-74.2 | 15.3-41.8 | 15.7-84.3 | 3.2-65.1 |
| CR, no. (%) | 9 (19) | 3 (6) | 4 (50) | 1 (12.5) |
| Marrow-CR, no. (%) | 5 (10) | 0 | 0 | 0 |
| Partial marrow response, no. (%) | 15 (31) | 10 (21) | 0 | 1 (12.5) |
| Not evaluable, no. (%) | 7 (15) | 10 (21) | 0 | 0 |
| No response, no. (%) | 12 (25) | 25 (52) | 4 (50) | 6 (75) |
| Hematologic response . | ALL . | LyBC . | ||
|---|---|---|---|---|
| All responses, N = 48 . | Sustained responses, N = 48 . | All responses, N = 8 . | Sustained responses, N = 8 . | |
| Overall, no. (%) | 29 (60) | 13 (27) | 4 (50) | 2 (25) |
| 95% CI, % | 45.3-74.2 | 15.3-41.8 | 15.7-84.3 | 3.2-65.1 |
| CR, no. (%) | 9 (19) | 3 (6) | 4 (50) | 1 (12.5) |
| Marrow-CR, no. (%) | 5 (10) | 0 | 0 | 0 |
| Partial marrow response, no. (%) | 15 (31) | 10 (21) | 0 | 1 (12.5) |
| Not evaluable, no. (%) | 7 (15) | 10 (21) | 0 | 0 |
| No response, no. (%) | 12 (25) | 25 (52) | 4 (50) | 6 (75) |
CI indicates confidence interval; CR, complete remission.